Condition: Germline BRCA-mutated HER2-negative Breast Cancer · Sponsor: Peking University People's Hospital
This study is an open-label, single-arm, multicenter clinical study. 64 patients with germline BRCA-mutated HER2-negative early breast cancer are planned to be enrolled and treated with fluzoparib combined with camrelizumab to observe and evaluate the efficacy and safety of neoadjuvant fluzoparib combined with camrelizumab in the treatment of germline BRCA-mutated HER2-negative early breast cancer。
This description comes directly from the study's public registry record.
Shu Wang, Dr. · 13801080201 · xiefei@pkuph.edu.cn
Fei Xie, Dr. · 13121969425 · xiefei@pkuph.edu.cn
Always discuss trial participation with your own doctor first.
| Breast Cancer, Peking University People's Hospital | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05576389